Gufic Biosciences
Gufic Biosciences is an Indian pharmaceutical company with a botulinum toxin type A manufacturing facility in Navsari, Gujarat. The company describes the facility and toxin work as a collaboration with Prime Bio in the United States, separating the Indian manufacturing node from the broader product-development relationship.
Gufic’s current NeuroCare materials identify Zarbot as its type A flagship product for therapeutic neurological conditions. Older company investor materials identify Stunnox Type A as an earlier Gufic botulinum toxin brand launched in February 2021. The available sources do not establish that the two names are the same product, a renamed product, or concurrently marketed products, so they should remain distinct pending clearer product documentation.
Quick Answers
Section titled “Quick Answers”| Question | Short answer |
|---|---|
| Is Gufic a botulinum toxin manufacturer? | Yes. Gufic describes a dedicated type A manufacturing facility in Navsari, Gujarat. |
| What is Zarbot? | Gufic identifies Zarbot as its current type A flagship product for therapeutic neurological conditions. |
| Is Zarbot the same as Stunnox? | The public materials reviewed here do not establish that relationship. Stunnox is an earlier Gufic product reference and Zarbot is a current one. |
| Does India-market availability establish approval elsewhere? | No. Each market’s label, approval, and product information must be checked independently. |
Reference Card
Section titled “Reference Card”| Field | Reference point |
|---|---|
| Company | Gufic Biosciences Limited |
| Corporate address | Mumbai, Maharashtra, India |
| Toxin facility | Navsari, Gujarat, India |
| Collaboration context | Prime Bio, United States, for botulinum toxin API and formulation work |
| Current product reference | Zarbot, botulinum toxin type A |
| Historical product reference | Stunnox Type A, launched in February 2021 according to company investor materials |
Manufacturing And Product Context
Section titled “Manufacturing And Product Context”Gufic describes the Navsari facility as dedicated to botulinum toxin type A manufacturing and identifies Prime Bio as a partner for API and formulation work. The company also frames Zarbot as an India-made therapeutic neurology product. Those statements establish company and product context, but they do not support comparisons of potency, safety, duration, or clinical superiority with another toxin brand.
The older Stunnox reference remains useful as an industry-history relationship. It should not, however, be used to infer a current label, presentation, or international availability without more recent product-specific sources.
Graph Connections
Section titled “Graph Connections”Gufic strengthens the India manufacturing map alongside Medyceles. The two pages represent different kinds of evidence: Gufic has a directly documented facility and current product reference, while Medyceles remains a more cautious regional manufacturer node.